中医传承辅助系统分析中医药治疗慢性肾小球肾炎的用药规律

目的 通过中医传承辅助平台(V2.5),采集中国期刊全文数据库(CNKI)、万方数据库(Wan Fang)和维普数据库(VIP)中文献数据,分析中医药治疗慢性肾小球肾炎的用药规律.方法 检索相关数据库2010-01至2019-12中医药治疗慢性肾小球肾炎的文献,收集相应方剂录入中医传承辅助系统,建立数据库,采用平台集成...     

《国际医学放射学杂志》2010年征订启事

《国际医学放射学杂志》(原《国外医学临床放射学分册》)于1978年创刊,由中华人民共和国卫生部主管,天津市医学科学技术信息研究所主办,主编为祁吉教授。本刊是中国核心期刊(遴选)数据库全文收录期刊、中国科学论文与引文数据库统计源期刊、中国期刊全文数据库全文收     

《中国介入影像与治疗学》杂志2009年征订启事

《中国介入影像与治疗学》杂志创刊于2004年,是由中国科学院主管,中国科学院声学研究所主办,中国工程院医药卫生工程学部协办的国家级学术期刊,主编为张金山教授、蒋学祥教授和李彦豪教授。刊号:ISSN1672-8475,CN11-5213/R。是中国核心期刊(遴选)数据库全文收录期刊、中国科技论文与引文数据库统计源期刊、中国期刊全文数据库全文收录期刊、荷兰《医学文摘》收录源期刊、俄罗斯《文摘杂志》收录源期刊、波兰《哥白尼索引》收录源期刊。     

《中国介入影像与治疗学》杂志2014年征订启事

《中国介入影像与治疗学》杂志创刊于2004年,是由中国科学院主管,中国科学院声学研究所主办,中国工程院医药卫生工程学部协办的国家级学术期刊,主编为邹英华教授。刊号:ISSN 1672-8475,CN 11-5213/R。是中国精品科技期刊、中国科技论文统计源期刊(中国科技核心期刊)、中国科学引文数据库核心期刊、中国期刊全文数据库全文收录期刊、     

国际医学放射学杂志

正International Journal of Medical Radiology本刊为双月刊,单月15日出版,国内外公开发行单册定价23元,全年6期,定价138元全国各地邮局均可订阅,也可直接向编辑部订购邮发代号:6-21国内统一刊号:CN 12-1398/R国际标准刊号:ISSN 1674-1897期刊简介《国际医学放射学杂志》(原《国外医学临床放射学分册》)于1978年创刊,由天津市医学科学技术信息研究所和天津市人民医院联合主办。本刊是中文核心期刊(2020年版)、中国科技论文统计源期刊(中国科技核心期刊)、中国科学论文与引文数据库统计源期刊、中国期刊全文数据库全文收录期刊。     

《中国医学影像学杂志》稿约

《中国医学影像学杂志》是由中华人民共和国卫生部主管、中国医学影像技术研究会主办的全国性专业学术期刊,1993年创刊,国内外公开发行。本杂志为中国中文核心期刊、中国科技论文统计源期刊(中国科技核心期刊)、中国科学引文数据库来源期刊、中国学术期刊综合评价数据库统计源期刊,并是中国科技期刊(遴选)数据库、中国科技论文统计数据库、中国学术期刊综合评价数据库、中国核心期刊(遴选)数据库、中国期刊全文数据库(CJED)、中国科学引文数据库、中国生物医学期刊数据库、中文科技期刊数据库(全文版)、中文生物医学期刊引文数据库、中国学术期刊(光盘版)收录期刊。杂志的办刊宗旨是:贯彻党和国家的卫生工作政策,坚持理论     

期刊简介

正《国际医学放射学杂志》(原《国外医学临床放射学分册》)于1978年创刊,由天津市医学科学技术信息研究所和天津市人民医院联合主办。本刊是中文核心期刊(2017年版)、中国科技论文统计源期刊(中国科技核心期刊)、中国科学论文与引文数据库统计源期刊、中国期刊全文数据库全文收录期刊。     

国际医学放射学杂志

正期刊简介《国际医学放射学杂志》(原《国外医学临床放射学分册》)于1978年创刊,由天津市医学科学技术信息研究所和天津市人民医院联合主办。本刊是中文核心期刊(2020年版)、中国科技论文统计源期刊(中国科技核心期刊)、中国科学论文与引文数据库统计源期刊、中国期刊全文数据库全文收录期刊。     

《中国介入影像与治疗学》杂志2008年征订启事

《中国介入影像与治疗学》杂志于2004年创刊,是由中国科学院主管,中国科学院声学研究所主办,中国工程院医药卫生工程学部协办的国家级学术期刊,主编为张金山教授、蒋学祥教授、李彦豪教授。刊号:ISSN1672-8475,CN11-5213/R。本刊是中国核心期刊(遴选)数据库全文收录期刊、中国科技论文与引文数据库统计源期刊、中国期刊全文数据库全文收录期刊、荷兰《医学文摘》收录源期刊、俄罗斯《文摘杂志》收录源期刊。《中国介入影像与治疗学》杂志以报道介入影像与治疗学、介入超声学、介入材料学、介入药物学与护理学等方面的临床研究、基础研究…     

复方丹参滴丸对糖尿病肾病患者尿蛋白及血脂水平的Meta分析

目的系统评价复方丹参滴丸对糖尿病肾病患者尿蛋白及血脂水平的影响。方法计算机检索The Cochrane Library(2013年第3期)、美国医学文摘数据库、中国生物医学文献数据库、中国期刊全文数据库、中文科技期刊全文数据库维普和万方数据库,检索年限均为1990年1月—2014年5月,公开发表的复方丹参滴丸治疗糖尿病肾病的随机对照研究,提取资料后采用Rev Man 5.2统计学软件进行Meta分析。结果共纳入14篇随机对照试验,合计1010名患者。Meta分析结果显示,复方丹参滴丸能显著减少糖尿病肾病的尿微量蛋白排泄率〔MD=-14.78,95%CI(-21.11,-8.45),P<0.01〕、尿微量白蛋白〔MD=-60.36,95%CI(-68.92,-51.80),P<0.01〕和血总胆固醇水平〔MD=-0.99,95%CI(-1.51,-0.46),P<0.01〕,但不能显著降低24 h尿蛋白定量〔MD=-0.12,95%CI(-0.22,-0.03),P=0.01〕和血甘油三酯水平〔MD=-0.61,95%CI(-1.10,-0.12),P=0.01〕。结论文献数据表明,复方丹参滴丸能减少糖尿病肾病患者的尿蛋白和血脂水平。     

X-ray computed tomography of hydatid cyst of the liver: symptomatology and classification. Apropos of 157 cases including 146 surgically confirmed

Computed tomography (CT) and in most cases ultrasonography imaging was carried out in 157 patients with suspected hydatid cyst of liver (HCL), and the diagnosis was confirmed on operation in 146 cases. Findings enabled enrichment of CT semiology, proposals for a classification of HCL and precision concerning the value of CT for diagnosis of this affection. The CT scan was observed to provide data on the lesions and to establish the diagnosis of HCL in almost all patients (only one false positive in the 146 cases operated upon). It appeared to be a more reliable method than other exploratory examinations, particularly ultrasonography, in a good number of cases. The indications for CT are defined and the place of this examination in overall investigatory procedures discussed.     

Intraarterial lidocaine for pain control after uterine artery embolization for leiomyomata

PURPOSE: To evaluate the effectiveness of intraarterial lidocaine in controlling pain after uterine artery embolization (UAE). MATERIALS AND METHODS: In this double-blind prospective study, patients undergoing UAE received preservative-free 1% lidocaine or saline solution (control) in the uterine arteries before embolization. Postprocedural pain was managed with patient-controlled intravenous morphine. Attempted doses, number of doses received, total morphine dose, and maximum pain numeric rating scale (NRS) score during the postprocedural hospitalization were recorded and compared. Three-month follow-up magnetic resonance (MR) imaging and symptomatic questionnaires were collected and compared. RESULTS: Ten patients received lidocaine and eight patients received placebo. Moderate to severe vasospasm was noted in seven patients after lidocaine injection, whereas no vasospasm was noted in the placebo group (P =.004). Patients in the lidocaine group had lower NRS pain scores than those in the placebo group (P =.012), whereas there was no difference in morphine requirement between treated patients and control subjects. The study was terminated after 18 patients were treated as a result of unexpected vasospasm. CONCLUSIONS: Intraarterial 1% lidocaine is associated with moderate to severe vasospasm. Lidocaine significantly lowers subjective pain, but there is no difference in analgesic requirements. The routine use of intraarterial lidocaine is not recommended for pain control until the long-term effects of vasospasm on outcome is known.     

Concentrations of monoethylglycinexylidide in body fluids of deceased patients after use of lidocaine for endotracheal intubation

The objective of this study was to determine whether the postmortem concentrations in body fluids of monoethylglycinexylidide (MEGX), a major active metabolite of lidocaine, reflect the circulatory state during cardiopulmonary resuscitation following endotracheal intubation using lidocaine. The concentrations of lidocaine and MEGX in blood, pericardial fluid, bile and/or urine were measured for sixteen patients who had received endotracheal intubation using Xylocaine jelly, a 2% w/v lidocaine hydrochloride preparation. Lidocaine was detected in all of the sixteen cases. Of six patients who had survived 3 h to 10 d following endotracheal intubation, four were MEGX-positive and two were negative. No MEGX was detected in the other ten patients whose hearts had not resumed beating despite attempts at cardiopulmonary resuscitation. MEGX can be an indicator of the vital state of a patient during cardiopulmonary resuscitation; it shows the antemortem use of lidocaine under normal hepatic conditions.     

A case of sudden death after gingival injection of a therapeutic dose of lidocaine: distribution of lidocaine in whole blood and various tissues

We report a case of sudden death after gingival injection of lidocaine, which made us suspect overdosing or anaphylactic shock. Using liquid chromatography-mass spectrometry (LC-MS), we measured the lidocaine concentrations in whole blood and tissues including the gingivae. The lidocaine concentration in blood (0.70 μg/ml) was lower than the therapeutic level. Lidocaine levels distributed to various organs were also low. Among them, the lung showed the highest level, followed by the liver, brain, and spleen. The concentrations in the gingivae with and without pus were 938 μg/g and 1048 μg/g, respectively. Together with the above analytical data, we made histopathological examinations, and tryptase and immunoglobulin E (IgE) assays as markers of anaphylactic shock. Macroscopically, myocardial ischemic changes were observed over relatively large areas. In such cardiac areas, there were focal necrosis, disarrangement of cardiac muscles, and stromal edema microscopically. The tryptase value was within the normal range. By carefully considering all data obtained from the victim, we diagnosed that the victim died of heart failure under the stress of the dental treatment.     

The use of intra-arterial lidocaine to control pain due to aortofemoral arteriography.

Intra-arterial lidocaine has been utilized to decrease pain by administration prior to contrast material injections during aortofemoral arteriography in over 600 patients. Because this observation was uncontrolled, a double-blind study was performed in 15 patients comparing the effectiveness of intra-arterial lidocaine and saline in the control of pain from contrast material injections (methylglucamine iothalamate) in pelvic and peripheral arteriography. Two per cent lidocaine was compared with 1% lidocaine in the same manner in an additional 10 patients. Peripheral vein blood samples were obtained in 4 patients to measure the plasma concentration of lidocaine. Intra-arterial lidocaine is safe and effective in reducing pain from intra-arterial contrast agent injections.     

我国医疗照射与保健水平的相关性研究

目的 对我国保健水平（HCL）及其影响因素进行研究。方法 利用国家统计局《中国统计年鉴》和公开文献中的数据,以全国和各省份人口和医师数量计算HCL。采用多元回归分析HCL与地区人口、面积、行政区划数量、国内生产总值（GDP）等因素间的关系。采用Pearson相关分析保健水平与医疗照射频度间关系。结果 我国从2015年起HCL值低于1 000,到2019年尚有两个省份HCL值>1 000;人口、GDP是HCL的影响因素,相关系数分别为0.416和-0.583;HCL和人群的医疗照射频度间具有一定相关性（r=-0.620,P=0.028）。结论 我国2020年的HCL值为542,各省份之间差异较大。HCL在中国作为医疗照射水平的评价指标需要进一步研究。     

Tissue and body fluid distribution of lidocaine and monoethylglycinexylidide in critical care patients who survived for various periods

We investigated the tissue and body fluid distribution of lidocaine and monoethylglycinexylidide (MEGX), an active metabolite of lidocaine, in 20 critical care patients who received lidocaine jelly for intubation, and survived for various periods after treatments. Our study population consisted of seven patients (Group A) who were transported to hospitals in conscious state and survived for 1–56 h, six patients (Group B) who arrived at hospitals in comatose state and survived for 5–91 h, and seven patients (Group C) who were in cardiopulmonary arrest on arrival at hospitals and survived for 3–59 h after their heartbeat was recovered by cardiopulmonary resuscitation. At autopsy, blood from different sources, cerebrospinal fluid, the cerebrum, lung, liver, kidney, and femoral muscle were collected from each cadaver for analysis of lidocaine and MEGX by gas chromatography with flame thermionic detection. This is the first report dealing with detailed distribution of MEGX in human tissues and body fluids for critical care patients. All patients were positive for lidocaine. MEGX was detected in five patients from Group A, all patients from Group B, and four patients from Group C. The liver-to-kidney ratios for lidocaine/MEGX were 0.28–1.76/0.50–0.67, and the cerebrum-to-cerebrospinal fluid ratios for lidocaine/MEGX were 0.54–3.63/1.81–3.13, respectively, for Group A; 0.14–0.55/0.05–0.59 and 1.22–4.00/1.64–3.44, respectively, for Group B; 0.22–0.95/0.68–1.28 and 1.15–6.44/10.2, respectively, for Group C. The concentration ratios of MEGX to lidocaine in blood in Groups A, B, and C were in the ranges of 0.01–1.08, 0.08–0.76, and 0.09–0.38, respectively. Based on our results, we propose that the measurements of MEGX distribution together with that of precursor lidocaine in various tissues and body fluids are useful for accurate assessment of the state of patients who receive medical treatment that is followed by death. The MEGX-to-lidocaine ratio in blood seems to be a useful test for evaluating antemortem liver function.     

Intraarterial Lidocaine Administration for Relief of Pain Resulting from Transarterial Chemoembolization of Hepatocellular Carcinoma: Its Effectiveness and Optimal Timing of Administration

PURPOSE: Patients undergoing transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) commonly have significant post-procedural abdominal pain necessitating narcotic administration. It is known that intraarterial administration of lidocaine is effective in controlling the pain during the procedure. However, optimum timing of the lidocaine administration is not precisely known. The purpose of this study was to assess the efficacy of intraarterial lidocaine administration for control of pain resulting from TACE and to evaluate the optimal timing of administration. METHODS: In a prospective trial, 113 consecutive patients with HCC who underwent TACE were classified into three groups: those who received a lidocaine bolus intraarterially immediately prior to TACE (group A, n = 30), those who received lidocaine immediately after TACE (group B, n = 46), and those who did not received lidocaine (group C, n = 37). Incidence and degree of post-procedural pain was assessed using a subjective method (visual analogue scales scored from 0 to 10) and an objective method (amount of post-procedural analgesics). RESULTS: The incidence of post-procedural pain in group A (16.7%) was significantly lower than that of group B (38.3%; p = 0.005). The mean pain score was 3.0 in group A and 4.8 and 3.1 in groups B and C, respectively. The mean dose of analgesic used after the procedure in group A (25.0 mg) was significantly lower than those in group B (52.9 mg) and group C (41.0 mg; p = 0.002). CONCLUSIONS: Pre-TACE intraarterial administration of lidocaine is much more effective than post-TACE administration in reducing the incidence and the severity of post-procedural pain. Furthermore, in order to reduce the incidence of post-procedural pain and dose of post-procedural analgesics, we recommend routine pre-TACE administration of lidocaine because post-procedural pain might developed even in patients who did not feel any pain during the TACE.     

经动脉内灌注利多卡因-碘油乳剂在恶性肿瘤栓塞化疗术中止痛疗效的评价

目的　评价经动脉内给予利多卡因 碘油乳剂行栓塞化疗术中控制疼痛和预防动脉痉挛的可行性和有效性 ,并探讨其最佳用量。方法　 1 2 0例恶性肿瘤患者均行栓塞化疗术 (TACE) ,随机分成3组 :行利多卡因 碘油乳剂栓塞者为A组 (n =4 0 ) ;TACE术前行利多卡因团注者为B组 (n =4 0 ) ,单纯TACE为C组者 (无利多卡因组 ,n =4 0 )。术后疼痛程度用一主观指标评价 (即视觉模拟等级 VAS 0 - 1 0)和一客观指标评价 (术后肌注镇痛剂的使用数量 ) ,术中动脉痉挛发生率通过DSA来评价。结果　 3组间疼痛发生率的差异有显著性 (P <0 .0 5 ) ,A ,B ,C组平均积分分别为 2 .78,3.87和 4 .4 6。术后疼痛积分提示A组较B组和C组显著降低 (P <0 .0 5 ) ,但B组和C组间差异无显著性 (P >0 .0 5 )。肌注镇痛剂控制难以忍受疼痛的药量上A组和B组患者均较C组有显著减少 (P <0 .0 5 ) ,A组和B组患者动脉痉挛发生率差异无显著性 ,但两者均较C组低 ,恶性肿瘤内碘油沉积在A组患者中最致密 ,尤其是在肝脏转移性肿瘤中碘油沉积更好。结论　经动脉灌注利多卡因 碘油乳剂行栓塞化疗术不但能减轻疼痛发生率 ,而且能阻止动脉痉挛的发生。它较术前给予哌替啶等强效镇痛剂和术中动脉灌注利多卡因更有效     

肝癌TACE术中应用利多卡因的效果观察

目的观察肝癌TACE术注入栓塞剂前应用利多卡因联合规范围手术期护理,对包括老年人群在内的肝癌患者的镇痛效果及对睡眠和生活质量的影响。 方法将100例拟行TACE术肝癌患者,按入院先后顺序分为两组各50例。两组均给予规范围手术期护理,观察组在TACE术中注入栓塞剂前一次性注入盐酸利多卡因注射液100 mg,对照组在注入栓塞剂前不注入利多卡因。两组均采用疼痛评分（视觉模拟评分法）、癌症患者生活质量量表、Spiegel量表评估两组术前、术后24 h疼痛、生活质量、睡眠情况。 结果两组术前生活质量评分、Spiegel量表评分比较及疼痛评分均无统计学意义（P > 0.05）。术后24 h生活质量评分,观察组（35.08 ± 9.50）与对照组（38.72 ± 10.9）比较无统计学意义（P > 0.05）,观察组优于对照组;术后24 h Spiegel量表评分,观察组（11.56 ± 2.31）与对照组（9.02 ± 2.69）比较均有统计学意义（P < 0.001）,观察组优于对照组;术后24 h疼痛视觉模拟评分,观察组（2.38 ± 1.47）与对照组（4.08 ± 1.59）比较有统计学意义（P < 0.001）,观察组优于对照组。 结论TACE术中注入栓塞剂前应用利多卡因联合规范围手术期护理,可以减轻肝癌患者包括老年人群在内的术后疼痛,改善其睡眠质量。